Renascience

Renascience EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Renascience (4889.T) as of Nov 22, 2026 is -356.89 M JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -178.77 M JPY — a change of 99.64% (lower).

EBITDA

-356.89 MJPY

YoY

99.64%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Renascience is 2026 -356.89 M JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Renascience was 2025 -178.77 M JPY. It decreases by 99.64% lower compared to the previous year.

The Renascience EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2020
-179.96 M JPY
Jan 1, 2021
-83.26 M JPY
Jan 1, 2022
-207.77 M JPY
Jan 1, 2023
-332.49 M JPY
Jan 1, 2024
-250.50 M JPY
Jan 1, 2025
-178.77 M JPY
Jan 1, 2026
-356.89 M JPY
The Renascience EBITDA history
YEAREBITDAYoY
-356.89 MJPY+99.64%
-178.77 MJPY-28.64%
-250.50 MJPY-24.66%
-332.49 MJPY+60.03%
-207.77 MJPY+149.55%
-83.26 MJPY-53.74%
-179.96 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Renascience is -356.89 M JPY in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Renascience changed from -178.77 M JPY to -356.89 M JPY, representing a 99.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Renascience since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Renascience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Renascience

All Key Metrics — Renascience